MOTS-c, exercise and CK2
A peptide encoded in mitochondrial DNA travels surprisingly far through the research. The exercise experiments are compelling; treatment in people remains unproved.
Mitochondrial DNA and a travelling peptide
Mitochondria are the parts of cells most associated with energy production. They also carry the instructions for MOTS-c, a 16-amino-acid peptide. That origin makes the cell experiments on its movement into the nucleus particularly interesting: under metabolic stress, MOTS-c moved into the compartment containing most of the cell’s DNA and helped regulate stress-response genes.
The experiments used human and mouse cells. “Stress” here means a disturbance in cellular conditions, including restricted fuel; it says nothing about relief from everyday worry.
I enjoy following MOTS-c from mitochondrial DNA to its effects in the nucleus. The familiar description of mitochondria as little power stations feels incomplete once something encoded there helps change gene activity elsewhere. This is already an interesting biological story before anyone tries to turn it into a treatment.
The mouse treadmill experiments
The 2021 exercise paper tested administered MOTS-c in mice aged 2, 12 and 22 months. It reported greater treadmill capacity and grip strength, with improved gait in aged mice. Exercise also increased naturally produced MOTS-c in muscle and circulation.
The older animals give the experiment its pull. A result involving movement and grip is more tangible than a change in a molecular marker, and its attraction as a claim about preserving physical capacity is obvious. Its limit is equally concrete: the treated subjects were mice. Human exercise-related changes in natural MOTS-c do not establish the effects of administering it.
The later CK2 experiments add a possible explanation for muscle effects, including protection against atrophy in mouse models. They also show the tissue difference that opens this site: CK2 activity increased in muscle and decreased in fat. A single, uniformly beneficial “boost” would be a poor description of that result.
Dialysis cohort
The human study I give particular space to followed 94 people receiving chronic hemodialysis, treatment that filters blood when kidneys cannot do enough of that work. Median follow-up was 26.5 months. Circulating MOTS-c was associated with a combined outcome of death from any cause or a non-fatal cardiovascular event, and it improved the investigators’ risk model.
Nobody in this study received MOTS-c as a treatment. The observation concerns the peptide already circulating in the participants’ blood.
I resist the leap from “associated with an outcome” to “adding more will improve that outcome.” The study makes a case for investigating a biomarker. It leaves the treatment question open, including which direction an intervention might push a complicated system.
MOTS-c: human safety gaps
The 2023 review brings the cellular, animal and observational work together. There are no completed human efficacy trials of administered MOTS-c, and no validated human half-life, bioavailability or dose-response. That leaves a large blank space around claims about combining it with an approved medicine.
MOTS-c is not FDA-approved for any use. Research material lacks the pharmaceutical oversight of an approved medicine; identity, purity and sterility can vary. WADA and USADA treat MOTS-c as prohibited in elite sport, with potential sanctions for athletes.
Some mechanistic findings still await replication, and several human biomarker studies are small or preliminary. MOTS-c intrigues me as biology; its case as a human treatment remains unfinished. The MOTS-c and tirzepatide FAQ follows that distinction through the combination question.